PCNT

Across TCGA pan-cancer cohorts, PCNT mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PCNT’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PCNT mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PCNT is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LSCC, PDAC, and HNSC are the cancer types where PCNT tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCNT mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	III,IV	−0.431	<.001	9	view →
PDAC	Female	III,IV	−0.514	<.001	8	view →
HNSC	All	III,IV	−0.173	<.001	8	view →
COAD	All	All	−0.309	<.001	7	view →
CCRCC	Male	All	−0.079	<.001	6	view →
LUAD	All	All	−0.074	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PCNT–LSCC

Open the LSCC breakdown →